NASDAQ Global Market • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD
SCYNEXIS, Inc. (SCYX) has a consensus analyst rating of Buy, based on 14 analysts covering the stock. Of those, 13 recommend buying, 1 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
